Vaccine最新文献

{"title":"Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil","authors":"Érique José Farias Peixoto de Miranda ,&nbsp;Rodrigo T. Calado ,&nbsp;Fernanda Castro Boulos ,&nbsp;José Alfredo de Sousa Moreira ,&nbsp;Fabiane Fernandes Machado ,&nbsp;Maria Aparecida Alves Leite Dos Santos Almeida ,&nbsp;Marcia Cristina Oliveira Da Rocha ,&nbsp;Vanessa Infante ,&nbsp;Laina D. Mercer ,&nbsp;Richard Hjorth ,&nbsp;Rami Scharf ,&nbsp;Jessica White ,&nbsp;Christina Polyak ,&nbsp;Rama Raghunandan ,&nbsp;Adolfo García-Sastre ,&nbsp;Weina Sun ,&nbsp;Peter Palese ,&nbsp;Florian Krammer ,&nbsp;Bruce Innis ,&nbsp;Cristiano Gonçalves Pereira ,&nbsp;Esper Georges Kallas","doi":"10.1016/j.vaccine.2024.126680","DOIUrl":"10.1016/j.vaccine.2024.126680","url":null,"abstract":"<div><div>COVID-19 continues to be a health issue, mainly due to virus circulation and the emergence of new variants of concern and interest.</div><div>This is a single-center, randomized, double-blind, active-controlled dose-escalating phase I clinical trial to evaluate the immunogenicity and safety of NDV-HXP-S (1 μg, 3 μg, and 10 μg), an inactivated COVID-19 vectored-vaccine virus using the Newcastle Disease Virus (NDV) expressing stabilized pre-fusion S protein from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Healthy SARS-CoV-2-naïve participants aged 18 to 59 years were randomized in a 3:3:3:1 ratio to receive two equal shots of 1 μg, 3 μg or 10 μg of NDV-HXP-S formulations or placebo/CoronaVac intramuscular 28 days apart, respectively. Primary endpoints were solicited adverse events (AEs) determined within 7 days after each dose (safety) and proportion of seroconversion and geometric mean of 50 % neutralizing titer ratios against SARS-CoV-2 Wuhan-hu-1, Beta, and Gamma strains, measured on Day 42 after the first dose (immunogenicity). Follow-up occurred for 12 months for safety and immunogenicity evaluation.</div><div>This study had substantial protocol amendments, the last one for early terminating the recruitment, as well as unblinding on Day 42. We included 311 subjects were in the safety population and 301 of them (97 %) received the second dose. More frequent solicited AEs were pain at the application site (&lt;89 %), headache (&lt;69 %), fatigue (&lt;68 %), and myalgia (&lt;61 %); most were classified as mild or moderate. There was no vaccine-related serious or grade-4 solicited AE. The proportion of participants reporting a vaccine-related unsolicited AE within 28 days after each dose ranged from 30 % to 33 % after the first dose and 14 % and 18 % after the second in NDV-HXP-S, comparable to the control group. The 10 μg NDV-HXP-S formulation was the one that elicited the higher seroconversion values and neutralizing antibodies on Day 42 against SARS-CoV-2 strains. Up to 1-year follow-up, levels of bind antibodies remains about 2 log₁₀ BAU/mL and no vaccine-related serious adverse event was reported.</div><div>Two NDV-HXP-S shots at 10 μg elicited the higher seroconversion and neutralizing antibody titers against the SARS-CoV-2. The vaccine also displayed a very favorable safety profile. <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span><strong>,</strong> <span><span>NCT04993209</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"52 ","pages":"Article 126680"},"PeriodicalIF":4.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143534361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of a conserved cryptic epitope with cross-immunoreactivity in outer membrane protein K (OmpK) from Vibrio species","authors":"Jingsheng Lun ,&nbsp;Peng Zheng ,&nbsp;Xueji Liang ,&nbsp;Yihui Hu ,&nbsp;Lu An ,&nbsp;Guiqian Xiao ,&nbsp;Xinyi Chen ,&nbsp;Ying Chen ,&nbsp;Huisheng Gong ,&nbsp;Mingqi Zhong ,&nbsp;Yueling Zhang ,&nbsp;Zhong Hu","doi":"10.1016/j.vaccine.2025.126964","DOIUrl":"10.1016/j.vaccine.2025.126964","url":null,"abstract":"<div><div>Outer membrane protein K (OmpK) has been proven to be an ideal vaccine candidate for broad-spectrum cross-prevention against Vibriosis. However, due to the extensive biological and genetic diversity of <em>Vibrio</em> species, current OmpK subunit vaccines can only target different strains of the same bacterial species or closely related species and have difficulty providing promising cross-immunoprotection against more diverse <em>Vibrio</em> infections. In recent years, the development of epitope-focused vaccines has been described as the latest stage in the development of vaccine formulations, providing new ideas for the development of broad-spectrum <em>Vibrio</em> vaccines. Interestingly, a cryptic epitope (K7) was identified in OmpK from <em>Vibrio</em> species, which is itself immunogenic but is not involved in the immune response to intact OmpK. Epitope K7 is a 15-residue hairpin structure in OmpK predicted to contain a 6-residue extracellular turn region. Interestingly, unlike other highly variable extracellular long loops, epitope K7 is the only conserved extracellular short turn in OmpK, with a similarity of 33 % to 93 %. K7 homologous peptides stimulated the production of specific antibodies, confirming their high immunogenicity. Cross-immunoreactivity between K7 homologous and K7-induced antibodies was evaluated by peptide-based ELISA, western blot, and cell-based ELISA. Flow cytometry and immunofluorescence assay further confirmed that the native epitope K7 in OmpK is surface-exposed and therefore an extracellular target that binds to antibodies. Moreover, an antibody-dependent and complement-mediated serum bactericidal assay suggested that epitope K7-induced antibodies have vibriocidal activity. In conclusion, we identified a conserved cryptic epitope with cross-immunoreactivity in OmpK from <em>Vibrio</em> species. Our results suggest that epitope K7 could be an ideal candidate for the design of epitope-focused vaccines against diverse <em>Vibrio</em> infections.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 126964"},"PeriodicalIF":4.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143535400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro evaluation of multi-protein chimeric antigens in effectively clearing the blood stage of Plasmodium falciparum","authors":"Bhagyashree Deshmukh ,&nbsp;Dhruv Khatri ,&nbsp;Sanjay Kumar Kochar ,&nbsp;Chaitanya Athale ,&nbsp;Krishanpal Karmodiya","doi":"10.1016/j.vaccine.2025.126952","DOIUrl":"10.1016/j.vaccine.2025.126952","url":null,"abstract":"<div><div><em>Plasmodium falciparum</em>-induced malaria remains a fatal disease affecting millions of people worldwide. Mainly, the blood stage of malaria is highly pathogenic and symptomatic, rapidly damaging the host organs and occasionally leading to death. Currently, no vaccines are approved for use against the blood stage of malaria. Canonical vaccines in the past have selected the most immunodominant or essential protein to block the growth of the parasite. This strategy works efficiently for low-complexity organisms such as viruses and a few bacteria but has not shown promising results for a malaria vaccine. <em>Plasmodium</em> has a complex life cycle and vaccine candidates especially during blood stage are ineffective due to multiple gene families showing redundancy, immune evasion, and insufficient antibody titer. Herein, we demonstrate a strategy of combining multiple antigens from the blood stage of <em>Plasmodium falciparum</em> using only the most immunodominant peptide sequences as a way of tackling polymorphism and redundancy. We created three chimeric antigens targeting eight PfEMP1 proteins (chimeric varB) and eight merozoite surface proteins (chimeric MSP and InvP) by selecting and stitching B-cell epitopes. Our chimeric constructs show naturally circulating antibodies against individual peptides using epitope-mapping microarray as well as entire proteins in malaria-infected patients. We demonstrate that anti-varB antibodies are neutralizing in nature and significantly reduce the cytoadhesion on an organ-on-chip system with a microfluidic device mimicking physiological conditions. We have applied a Deep Learning based method to quantify the number of adhered RBCs under fluidic conditions that is used to study cytoadhesion. Furthermore, the anti-MSP and InvP antibodies show complete growth inhibition in a single cycle at a combined concentration of 0.13 mg/ml. Overall, our preliminary results show that a combination of antigenic peptides from multiple antigens can potentially effectively reduce cytoadhesion and clear blood stage infection in in-vitro settings.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 126952"},"PeriodicalIF":4.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143529534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An LNP-mRNA vaccine protects fish against rhabdovirus infection","authors":"Camille Ayad ,&nbsp;Dean Porter ,&nbsp;Elise Lambert ,&nbsp;Pierre Libeau ,&nbsp;Céline Coiffier ,&nbsp;Valentine Ginet ,&nbsp;Bertrand Collet ,&nbsp;Jean-Pierre Levraud ,&nbsp;Pierre Boudinot ,&nbsp;Bernard Verrier","doi":"10.1016/j.vaccine.2025.126957","DOIUrl":"10.1016/j.vaccine.2025.126957","url":null,"abstract":"<div><div>mRNA vaccines are poised to revolutionize disease prevention, following the approval of their administration to humans against SARS-CoV-2. Although they have been extensively studied for human applications, their potential in the veterinary field has not been explored yet. No mRNA vaccines have yet been reported for fish, despite the urgent need for new vaccines against emerging pathogens in aquaculture. As fish are ectotherms, temperature has an impact on their immune response and on many other biological parameters, including the composition of membrane lipids. It is therefore crucial to identify whether mRNA delivery systems are suitable for <em>in vivo</em> expression in fish for vaccine purposes. In the present study, we developed a proof of concept for mRNA vaccination in rainbow trout, a salmonid, demonstrating the efficacy of current vaccine delivery systems in fish. We used lipid nanoparticles (LNPs), which represent the most advanced delivery technology for mRNA. LNPs use a combination of lipid components that form an encapsulating structure offering protection and promote endosome escape of the mRNA to allow its expression. <em>In vitro</em> assays showed that LNPs are a powerful vehicle for mRNA delivery in fish cells without substantial toxicity. <em>In vivo</em> imaging in adult zebrafish (<em>Danio rerio</em>) demonstrated that intramuscular injection of LNP-formulated <em>egfp</em> mRNA resulted in local expression of eGFP for up to 7 days. An LNP-based mRNA vaccine candidate encoding the viral haemorrhagic septicaemia virus (VHSV) glycoprotein induced neutralizing antibodies in rainbow trout (<em>Oncorhynchus mykiss</em>) and offers almost complete protection against a lethal viral challenge. Our data constitute a first proof of concept of mRNA vaccination in fish, paving the way for new developments in veterinary vaccines for aquaculture.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 126957"},"PeriodicalIF":4.5,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing confidence for pediatric COVID-19 and influenza vaccines using messages affirming parental autonomy: A randomized online experiment","authors":"Lynne M. Cotter ,&nbsp;Molecula Hopkins-Sheets ,&nbsp;Sijia Yang ,&nbsp;Susan R. Passmore ,&nbsp;Mahima Bhattar ,&nbsp;Emma Henning ,&nbsp;Dan Schultz ,&nbsp;Emily Latham ,&nbsp;Malia Jones","doi":"10.1016/j.vaccine.2025.126947","DOIUrl":"10.1016/j.vaccine.2025.126947","url":null,"abstract":"<div><h3>Objectives</h3><div>To test the effects of autonomy-affirming pediatric vaccine messages for U.S. parents on overall vaccine confidence and intention to vaccinate against COVID-19 and flu while examining potential moderation effects of political ideology.</div></div><div><h3>Methods</h3><div>We conducted an online randomized messaging experiment with 1718 parents, balanced across political ideology (31 % conservative, 37 % moderate, 31 % liberal). We compared four types of vaccine messages: 2 (autonomy-confirming vs authoritarian tone) x 2 (COVID-19 or flu). Parents viewed three messages within a single condition and rated their overall vaccine confidence and intentions to vaccinate their children.</div></div><div><h3>Results</h3><div>Adjusted for covariates, we found significant interactions between autonomy-confirming language and ideology. Conservative parents who saw COVID-19 messages increased vaccine confidence in response to autonomy-confirming messages, compared to both moderate and liberal parents. For flu messages, we found that autonomy-confirming messages increased confidence and intention to vaccinate for conservative parents only.</div></div><div><h3>Discussion</h3><div>Messages promoting pediatric COVID-19 and flu vaccination were generally more effective at increasing overall confidence toward vaccines for conservative parents when using autonomy-confirming language.</div></div><div><h3>Conclusions</h3><div>Pediatric vaccinations are politicalized in the United States, and messaging strategies targeting parents must consider this. Public health agencies serving conservative parents can use autonomy-confirming messaging to positively influence parents' confidence in giving their children vaccines.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 126947"},"PeriodicalIF":4.5,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143529532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine hesitancy in the vaccination of children in Brazil","authors":"Ana Paula França ,&nbsp;Carla Magda Allan Santos Domingues ,&nbsp;Raissa Allan Santos Domingues ,&nbsp;Rita Barradas Barata ,&nbsp;Maria da Glória Teixeira ,&nbsp;Ione Aquemi Guibu ,&nbsp;José Cássio de Moraes","doi":"10.1016/j.vaccine.2025.126905","DOIUrl":"10.1016/j.vaccine.2025.126905","url":null,"abstract":"<div><div>Since 2016, there has been a decrease in vaccination coverage for the childhood schedule of the National Immunization Program (PNI) in Brazil. To identify the reasons for vaccine hesitancy, we conducted a household survey of 31,001 live-born children living in the 26 Brazilian state capitals and the Federal District in 2017 and 2018. Census tracts were stratified according to socioeconomic status, we interviewed parents and/or guardians to collect information on the mother, child, reasons for not vaccinating, and other data. To identify the determinants of vaccine hesitancy, were used the “5Cs” (confidence, complacency and convenience, communication and context). Confidence: 94.5 % of parents/guardians of children trust the vaccines; 98.4 % believe it is important to vaccinate their children, and 20,0 % believe that vaccines are associated with serious adverse events. Complacency: 96.7 % decided to vaccinate their children with all the vaccines recommended; 7.2 % experienced difficulties with vaccination (distance and opening hours of the vaccination service, lack of time, problems with the child's health) despite going to the vaccination appointment; 22.9 % did not vaccinate their children (vaccine unavailable, clinic closed, health care provider absent, fear of adverse events). Communication: 24.5 % decided not to take their child for vaccination because of the pandemic; 24.4 % feared a reaction to the vaccine, and 9.2 % did not have the vaccine recommended by their doctor or health care provider. Socioeconomic status: vaccine confidence was lower among mothers with low education levels and lower-income families. Conclusions: Operational difficulties in the health care network were the main reasons for vaccine hesitancy in Brazilian state capitals during the study period. Although the proportion of parents/guardians who do not vaccinate their children voluntarily is low, this is a problem that needs to be consider so that it does not increase over time due to the infodemic.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 126905"},"PeriodicalIF":4.5,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143529605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Designing a National Rapid Vaccine Coverage Survey in low-resource settings: Experiences from the Democratic Republic of the Congo 2018–2023","authors":"Eric M. Mafuta ,&nbsp;Aimée M. Lulebo ,&nbsp;Jean-Bosco N. Kasonga ,&nbsp;Nono M. Mvuama ,&nbsp;Christophe L. Luhata ,&nbsp;Nicole A. Hoff ,&nbsp;Dalau M. Nkamba ,&nbsp;Sydney Merritt ,&nbsp;John Samuel Otomba ,&nbsp;Branly K. Mbunga ,&nbsp;Aimé M.W.B. Cikomola ,&nbsp;Anne W. Rimoin ,&nbsp;Jean-Crispin Mukendi ,&nbsp;Jean Bernard LeGargasson ,&nbsp;Cyril Nogier ,&nbsp;Léon Kinuani ,&nbsp;Marcellin Mengouo Nimpa ,&nbsp;Daniel K. Ishoso ,&nbsp;Adèle N. Mudipanu ,&nbsp;Deo Manirakiza ,&nbsp;Paul-Samson D. Lusamba","doi":"10.1016/j.vaccine.2025.126956","DOIUrl":"10.1016/j.vaccine.2025.126956","url":null,"abstract":"<div><div>In the Democratic Republic of the Congo (DRC), estimating vaccine coverage (VC) has traditionally relied on large-scale surveys such as the Demographic and Health Surveys (DHS) and the Multiple Indicator Cluster Surveys (MICS). However, these surveys are infrequent, costly, and lack the granularity needed for decision-making at the health district or zone (HZ) level. This paper describes the development by the Kinshasa School of Public Health (KSPH), and technical partners of a Vaccine Coverage Survey (KSPH VCS), adapted from the World Health Organization (WHO) guidelines, which aims to provides timely, cost-effective, and representative estimates of VC at the HZ level.</div><div>The KSPH VCS adopted a cross-sectional design and a multi-stage sampling approach to sample households at the HZ level. It uses Health Area as cluster in spite of Enumeration Area, and extends the eligibility age range from 12 -23 months to 6–23 months. The sample size for each HZ was calculated using vaccine coverage provided in MICS-2018. It integrates assessments of barriers and enablers to vaccination. Since 2023, it has included malaria indicators. Since its inception in 2018, it has expanded nationwide, covering all 26 provinces of the DRC by 2022.</div><div>Findings from the KSPH VCS provides estimates at the HZ level that could be combined to provincial and national estimates. Results have been instrumental in evaluating national immunization strategies, including the Mashako Plan and informing Presidential Forums on immunization. They have informed resource allocation, operational planning, and policy decisions at both national and provincial levels as they provided granularity needed for operational decision-making at the HZ level. Its results have also contributed to global immunization estimates, including the WHO/UNICEF Estimates of National Immunization Coverage (WUENIC).</div><div>The KSPH VCS demonstrates the feasibility of a locally led, cost-effective, and adaptable VC survey in a low-resource setting. Its success highlights the potential for similar methodologies to be implemented in other low- and middle-income countries seeking to improve immunization monitoring and health system performance.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 126956"},"PeriodicalIF":4.5,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy for good practices","authors":"Sara Tengattini ,&nbsp;Teodora Bavaro ,&nbsp;Francesca Rinaldi ,&nbsp;Caterina Temporini ,&nbsp;Loredano Pollegioni ,&nbsp;Marco Terreni ,&nbsp;Luciano Piubelli","doi":"10.1016/j.vaccine.2025.126932","DOIUrl":"10.1016/j.vaccine.2025.126932","url":null,"abstract":"<div><div>Tuberculosis (TB) has plagued humanity in numerous devastating forms for centuries and remains a significant health challenge. <em>Mycobacterium tuberculosis</em> (Mtb), the bacterium responsible for TB, was the leading cause of death among infectious agents until the COVID-19 pandemic emerged. Immunization with the bacillus Calmette-Guérin (BCG) vaccine is one of the primary strategies to mitigate the risk of TB. Despite its widespread use, the current BCG vaccine has limited efficacy, particularly in adults. This review focuses on the rational design of vaccine candidates targeting the antigens TB10.4 and Ag85B. The review discusses the roles of TB10.4 and Ag85B in the virulence of Mtb and notes challenges in their production. Additionally, various protein conjugation strategies to enhance immunogenicity, including linking these antigens to glycans and adjuvants, are considered, as well as the most appropriate analytical methods for characterizing recombinant antigenic proteins and their conjugates. Finally, the associated challenges in developing a vaccine encompassing specific glycans and protein components were highlighted. We claim that using standardized procedures and detailed reporting in protein production and chemical modification can improve the reproducibility and rationalization of biological results. By adhering to these guidelines, the goal of developing an effective vaccine against TB will be best achieved.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 126932"},"PeriodicalIF":4.5,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel tetravalent influenza vaccine based on one chimpanzee adenoviral vector","authors":"Yixin Niu ,&nbsp;Yao Yan ,&nbsp;Ying Hu ,&nbsp;Xi Yang ,&nbsp;Hongyang Shi ,&nbsp;Ping Zhou ,&nbsp;Caihong Zhu ,&nbsp;Man Xing ,&nbsp;Dongming Zhou ,&nbsp;Xiang Wang","doi":"10.1016/j.vaccine.2025.126959","DOIUrl":"10.1016/j.vaccine.2025.126959","url":null,"abstract":"<div><div>Highly effective and broad-spectrum influenza vaccines are urgently required to prevent influenza outbreaks. Hemagglutinin (HA), M2 ectodomain (M2e), and nucleoprotein (NP) are crucial target antigens for the development of universal influenza vaccines. To generate a novel multivalent influenza vaccine, the <em>HA</em> genes of influenza B Yamagata (BY) and Victoria (BV) strains, and the <em>NP</em> gene of H1N1 were cloned into the E1 region of the chimpanzee adenoviral vector, AdC68, and M2e epitopes of H1N1 and H3N2 were fused to the loop region of the AdC68 fiber, resulting in the recombinant adenoviral vector vaccine, AdC-Flu-Tet. The immunoprotective effects of AdC-Flu-Tet were evaluated in the mouse models. The results showed that AdC-Flu-Tet successfully induced robust humoral and cellular immune responses and conferred full protection against H1N1, H3N2, BY, and BV infections. In conclusion, AdC-Flu-Tet is a promising candidate as a novel influenza vaccine with high protective efficacy.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 126959"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Workshop report: One Health challenges and knowledge gaps in the control of intracellular infections with a focus on tuberculosis and leishmaniasis","authors":"Michele Miller ,&nbsp;Maria Adelaida Gómez ,&nbsp;Rachel Tanner ,&nbsp;Samantha Vermaak ,&nbsp;Bernardo Villarreal-Ramos","doi":"10.1016/j.vaccine.2025.126929","DOIUrl":"10.1016/j.vaccine.2025.126929","url":null,"abstract":"<div><div>The VALIDATE Network brings together scientists addressing vaccine development for neglected infectious diseases caused by intracellular pathogens. In September 2023, the first workshop on One Health approaches to research and capacity building was held in Paarl, South Africa, with a focus on tuberculosis and leishmaniasis. Thirty-two scientists from 15 countries presented and discussed broad topics pertinent to zoonotic diseases, cross-species disease transmission, disease mitigation strategies, inequitable access to medicines and health technologies, and health system challenges in One Health. In this report, we summarize the gaps, challenges, and opportunities identified during the 2023 VALIDATE One Health workshop. We anticipate that the experiences and dialogues will be informative for animal, human, and environmental health investigators to guide the development of research projects and vaccine development with a One Health vision.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 126929"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143519999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}